choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Brilinta

Brilinta Newsletter
  • Astrazeneca buys drug fast-track voucher for $95m 22 Aug 2019 12:00 GMT

    pharmaceutical company. Read more: Astrazeneca faces setback in lung cancer trials … It bumps Astrazeneca up the FDA’s queue, but not … way to the top. FDA reviews normally take around … drugs are generally seen to include tagrisso, lynparza, imfinzi, brilinta, …

  • AZ shares spike on good second quarter led by cancer drugs 25 Jul 2019 11:48 GMT

    … a move up the treatment pathway into second- and … first-line treatment. The quarter consolidates Tagrisso … of course, along with cardiovascular drug Brilinta (ticagrelor) – up 28% … its HER2-targeting antibody-drug conjugate trastuzumab deruxtecan ( …

  • AstraZeneca gains £4bn in value after cancer drugs sales surge 25 Jul 2019 10:31 GMT

    … performances by its new cancer treatments, Tagrisso, Imfinzi and Lynparza. … heart disease drug Brilinta and diabetes medicine Farxiga, with all five drugs expected to … our new medicines AstraZeneca chief executive Pascal Soriot Oncology drugs and emerging …

  • Prediction Model Helps Flag Sound-Alike, Look-Alike Drugs 14 Jun 2019 12:23 GMT

    … for Safe Medication Practice's list of confused drug names as … SALA medications pairs. For a … the antidepressant Brintellix (Takeda) was confused with the blood thinner Brilinta (AstraZeneca …

  • Why the stock of this biotech has nearly tripled in 6 months 17 Apr 2019 20:40 GMT

    … Mow (formerly at Amylin Pharmaceuticals and Bristol-Meyers Squibb) … with the brand name Brilinta for prospective heart-attack … Del. A second trial for the treatment is scheduled for this … medical officer John Lee said the drug had passed earlier trials with …

  • PhaseBio's Latest FDA Designation Moves It One Step Closer To Potential Approval 17 Apr 2019 13:50 GMT

    drug Brilinta (Ticagrelor). With such a strong effect, the FDA had given the drug … who take Brilinta. For starters, PB2452 treatment has the … a two-week free trial period for subscribers … analysis of many pharmaceutical companies. The Biotech Analysis Central …

  • Why I've Started A Small Short In PhaseBio Pharmaceuticals 17 Apr 2019 12:15 GMT

    … small short position in PhaseBio Pharmaceuticals (PHAS), but let … antiplatelet drug ticagrelor, which we are developing for the treatment … a Phase 1 clinical trial of PB2452 in healthy … . Importantly, ticagrelor (brand names Brilinta, Brilique, and Possia) is …

  • Aggredyne passes US FDA clearance for ADP platelet aggregation testing cartridge 09 Apr 2019 09:28 GMT

    … US Food and Drug Administration (FDA) for its AggreGuide … effect of various antiplatelet medications. According to the company … of various antiplatelet medications that target the … FDA-approved combinations of dual anti-platelet therapies (Plavix, Brilinta

  • Buy Sun Pharmaceutical Industries, target Rs 581: Nirmal Bang Institutional Equities 06 Mar 2019 13:38 GMT

    … market price of Sun Pharmaceutical Industries is Rs 459. … one year when Sun Pharmaceutical Industries price can reach … effective treatment options. Cequa is apparently the first drug to … global innovator brands (Januvia, Brilinta and Forxiga). SPIL’s …

  • The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote 27 Feb 2019 03:19 GMT

    … GOSS) Homology Medicines Inc (NASDAQ: FIXX) Ionis Pharmaceuticals Inc (NASDAQ: … Drug Assessing data from the required post-marketing trial … AstraZeneca's Brilinta Found To Alleviate Cardiovascular … dexamethasone, for the treatment of patients with relapsed …

Satisfied with the content?

Continue to create your account.